.
MergerLinks Header Logo

Announced

Completed

BenevolentAI went public via a SPAC merger with Odyssey Acquisition in a $1.7bn deal.

Financials

Edit Data
Transaction Value£1,282m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

De-SPAC

Biotechnology

Domestic

Private

machine learning

Majority

Reverse Takeover

Private Equity

Single Bidder

United Kingdom

artificial intelligence

Friendly

Acquisition

Merger

Completed

Synopsis

Edit

BenevolentAI, a clinical-stage AI drug discovery company, went public via a SPAC merger with Odyssey Acquisition in a $1.7bn deal. The transaction includes a c.$152m PIPE from Temasek, AstraZeneca, Ally Bridge Group and Invus. "The combination with Odyssey will allow us to scale our vision and ambition of uniting purposeful technology and cutting-edge science to discover life-changing medicines," Joanna Shields, BenevolentAI CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US